DexCom, Inc.
$79.50
+0.88 · +1.12% today
Market open · updated 12:44:26 PM ET
- High
- $81.43 4:05 AM
- Low
- $79.14 4:10 AM
Against the S&P 500 Price change through Oct 28, 2026
DXCM+18.46%
S&P 500+13.26%
DXCM+13.56%
S&P 500+12.41%
DXCM−11.95%
S&P 500+88.06%
DXCM−44.86%
S&P 500+68.51%
Key numbers
- Previous close
- $78.62
- Open
- $79.08
- Day's range
- $78.60 – $79.65
- 52-week range
- $54.11 – $92.59
- Volume
- 1.7 million
- Average volume
- 4.5 million
- Market value
- $30.0 billion
- Price to earnings
- 30.4last 12 months
- Earnings per share
- $2.61last 12 months
- Beta
- 1.48moves about 1.5× as much as the market
- Dividend
- None
- 50-day average
- $86.18
- 200-day average
- $74.45
Thursday, Oct 29, 2026, after the close.
Analyst price targets and the full financials are in the terminal.
Who DexCom buys from and competes with From our value chain
DexCom in the news
- HeadlineDexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in NovemberBusiness Wire · October 28, 2026 at 8:00 AM ET
- HeadlineDid DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PRNewsWire · October 27, 2026 at 3:29 PM ET
- HeadlineDexCom Gears Up to Report Q3 Results: How to Play the Stock?Zacks Investment Research · October 26, 2026 at 3:00 PM ET
- Market closeS&P 500, Dow and Nasdaq Close Higher as Tech Leads Wednesday RallyWiseView Research desk · October 21, 2026
- HeadlineDexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT StudyZacks Investment Research · October 20, 2026 at 11:50 AM ET
- HeadlineDexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave ArrivesSeeking Alpha · October 17, 2026 at 11:41 PM ET
- HeadlineHealth Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulinReuters · October 15, 2026 at 7:30 PM ET
- CongressRo Khanna bought $1,001 - $15,000 of DXCMHouse filing · disclosed Jun 11, 2026
Earnings
Next report: Thursday, Oct 29, 2026, after the close.
Congress trades in DXCM
6 purchases and 2 sales in the latest 8 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | May 1, 2026 | Jun 11, 2026 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Apr 13, 2026 | May 13, 2026 |
| John BoozmanSenate · R-Arkansas | Purchase | $1,001 - $15,000 | Jan 26, 2026 | Feb 15, 2026 |
| Michael McCaulHouse · R-Texas | Purchase | $1,001 - $15,000 | Sep 22, 2025 | Oct 13, 2025 |
| Ro KhannaHouse · D-California | Sale | $1,001 - $15,000 | Sep 29, 2025 | Oct 3, 2025 |
| Michael McCaulHouse · R-Texas | Sale | $15,001 - $50,000 | Jun 16, 2025 | Jul 9, 2025 |
| Michael McCaulHouse · R-Texas | Purchase | $15,001 - $50,000 | Jun 2, 2025 | Jul 9, 2025 |
| Rob BresnahanHouse | Purchase | $1,001 - $15,000 | May 15, 2025 | Jun 10, 2025 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About DexCom
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 11,050
- Headquarters
- San Diego, California
- Website
- dexcom.com
- Listed
- Apr 14, 2005
More medical - devices stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.